$PAND +133% today an acquisition news

$PAND who is a clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases just today after Merck & Co ($MRK) offer $60 per share in cash.

Here is the link of the press release.

Here is the graph of the day.

 

Here is the 30-day overview.

You May Also Like

$XELA +175% on 90M$ contract

$EYES jump + 304% on FDA aproval.

$COHN +133% today!

$MORF + 134% today.

Leave a Reply

Your email address will not be published. Required fields are marked *

EMAIL SIGNUP